No instances of CIDP or MMN were seen during clinical trials of the two vaccines. Neither the Centers for Disease Control and Prevention (CDC) nor the Food and Drug Administration (FDA) recommends against administration of the Covid 19 vaccine in patients with CIDP or MMN. One must keep in mind that the Covid Vaccine has only been used for 4-6 weeks outside of the clinical trials and it is too early to offer scientific statements on long-term adverse effects of the vaccine in CIDP or MMN. Even though there is no long term data yet, there is no scientific reason to think that the vaccine will cause problems in those patients with CIDP or MMN. It is suggested to avoid vaccination in the week following IVIg, as this may potentially lessen the efficacy of the vaccination.